Non-Alcoholic Steatohepatitis (NASH) – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Non-Alcoholic Steatohepatitis (NASH) – Pipeline Review, H2 2018’, provides an overview of the Non-Alcoholic Steatohepatitis (NASH) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis (NASH), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis (NASH) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis (NASH)

– The report reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Non-Alcoholic Steatohepatitis (NASH) therapeutics and enlists all their major and minor projects

– The report assesses Non-Alcoholic Steatohepatitis (NASH) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis (NASH)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis (NASH) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abide Therapeutics Inc

AdAlta Ltd

Akcea Therapeutics Inc

Albireo Pharma Inc

Aldeyra Therapeutics Inc

Allergan Plc

Araim Pharmaceuticals Inc

Arcturus Therapeutics Ltd

Ardelyx Inc

Ascletis Inc

Assembly Biosciences Inc

AstraZeneca Plc

Baliopharm AG

Betagenon AB

BioElectron Technology Corp

Bird Rock Bio Inc

BLR Bio LLC

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Cadila Healthcare Ltd

Can-Fite BioPharma Ltd

Cardax Inc

Carmot Therapeutics Inc

Catabasis Pharmaceuticals Inc

Celgene Corp

Cerenis Therapeutics Holding SA

ChemoCentryx Inc

CJ HealthCare Corp

CohBar Inc

ConSynance Therapeutics Inc

CymaBay Therapeutics Inc

Daiichi Sankyo Co Ltd

Debiopharm International SA

Dicerna Pharmaceuticals Inc

Dimerix Bioscience Pty Ltd

Dong-A Socio Holdings Co Ltd

DURECT Corp

Eli Lilly and Co

Enanta Pharmaceuticals Inc

Enyo Pharma SA

Esperion Therapeutics Inc

Exicure Inc

Forma Therapeutics Inc

Galectin Therapeutics Inc

Galecto Biotech AB

Galmed Pharmaceuticals Ltd

Gemphire Therapeutics Inc

Genfit SA

GenKyoTex SA

Gilead Sciences Inc

GRI Bio Inc

Guangdong Zhongsheng Pharmaceutical Co Ltd

Hanmi Pharmaceuticals Co Ltd

HemoShear Therapeutics, LLC

IB Pharmaceuticals Inc

iCo Therapeutics Inc

Immupharma Plc

Immuron Ltd

Integral Molecular Inc

Intercept Pharmaceuticals Inc

Inventiva

Ionis Pharmaceuticals Inc

Kissei Pharmaceutical Co Ltd

Kowa Co Ltd

Kyorin Pharmaceutical Co Ltd

Madrigal Pharmaceuticals Inc

MallInckrodt Plc

MedImmune LLC

Merck & Co Inc

Metabolys SAS

Metacrine Inc

Mina Therapeutics Ltd

Mitsubishi Tanabe Pharma Corp

Naia Ltd

NeuroVive Pharmaceutical AB

NGM Biopharmaceuticals Inc

Nippon Chemiphar Co Ltd

NorthSea Therapeutics BV

Novartis AG

NovaTarg Therapeutics Inc

Novo Nordisk AS

Nuevolution AB

NuSirt Biopharma Inc

Oramed Pharmaceuticals Inc

Pfizer Inc

Pharmaxis Ltd

Poxel SA

Promethera Biosciences SA

ProMetic Life Sciences Inc

Protalix BioTherapeutics Inc

Redx Pharma Plc

Regulus Therapeutics Inc

reMYND NV

Ritter Pharmaceuticals Inc

Saje Pharma LLC

Sancilio & Company Inc

Sanofi

ScandiCure AB

Second Genome Inc

Seres Therapeutics Inc

Shire Plc

Sprint Bioscience AB

Synlogic Inc

TaiwanJ Pharmaceuticals Co Ltd

Terns Pharmaceuticals Inc

Tiziana Life Sciences Plc

TRACON Pharmaceuticals Inc

Vascular Biogenics Ltd

Verlyx Pharma Inc

Viking Therapeutics Inc

Visionary Pharmaceuticals Inc

WAVE Life Sciences Ltd

Zafgen Inc

Zebra Discovery Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Non-Alcoholic Steatohepatitis (NASH) - Overview 8

Non-Alcoholic Steatohepatitis (NASH) - Therapeutics Development 9

Non-Alcoholic Steatohepatitis (NASH) - Therapeutics Assessment 35

Non-Alcoholic Steatohepatitis (NASH) - Companies Involved in Therapeutics Development 51

Non-Alcoholic Steatohepatitis (NASH) - Drug Profiles 101

Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects 563

Non-Alcoholic Steatohepatitis (NASH) - Discontinued Products 567

Non-Alcoholic Steatohepatitis (NASH) - Product Development Milestones 568

Appendix 578

List of Tables

List of Tables

Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..5), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..6), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..7), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..8), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Products under Development by Companies, H2 2018 (Contd..5), H2 2018

Products under Development by Companies, H2 2018 (Contd..6), H2 2018

Products under Development by Companies, H2 2018 (Contd..7), H2 2018

Products under Development by Companies, H2 2018 (Contd..8), H2 2018

Products under Development by Companies, H2 2018 (Contd..9), H2 2018

Products under Development by Companies, H2 2018 (Contd..10), H2 2018

Products under Development by Companies, H2 2018 (Contd..11), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..2), H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..3), H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..4), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..2), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..3), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..4), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Abide Therapeutics Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by AdAlta Ltd, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Akcea Therapeutics Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Albireo Pharma Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Aldeyra Therapeutics Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Allergan Plc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Araim Pharmaceuticals Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Arcturus Therapeutics Ltd, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Ardelyx Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Ascletis Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Assembly Biosciences Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by AstraZeneca Plc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Baliopharm AG, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Betagenon AB, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by BioElectron Technology Corp, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Bird Rock Bio Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by BLR Bio LLC, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Boehringer Ingelheim GmbH, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Bristol-Myers Squibb Co, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Cadila Healthcare Ltd, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Can-Fite BioPharma Ltd, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Cardax Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Carmot Therapeutics Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Catabasis Pharmaceuticals Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Celgene Corp, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Cerenis Therapeutics Holding SA, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by ChemoCentryx Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by CJ HealthCare Corp, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by CohBar Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by ConSynance Therapeutics Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by CymaBay Therapeutics Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Debiopharm International SA, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Dicerna Pharmaceuticals Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Dimerix Bioscience Pty Ltd, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Dong-A Socio Holdings Co Ltd, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by DURECT Corp, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Eli Lilly and Co, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Enanta Pharmaceuticals Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Enyo Pharma SA, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Esperion Therapeutics Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Exicure Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Forma Therapeutics Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Galectin Therapeutics Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Galecto Biotech AB, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Galmed Pharmaceuticals Ltd, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Gemphire Therapeutics Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Genfit SA, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by GenKyoTex SA, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Gilead Sciences Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by GRI Bio Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by HemoShear Therapeutics, LLC, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by IB Pharmaceuticals Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by iCo Therapeutics Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Immupharma Plc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Immuron Ltd, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Integral Molecular Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Intercept Pharmaceuticals Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Inventiva, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Ionis Pharmaceuticals Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Kissei Pharmaceutical Co Ltd, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Kowa Co Ltd, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Madrigal Pharmaceuticals Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by MallInckrodt Plc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by MedImmune LLC, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Merck & Co Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Metabolys SAS, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Metacrine Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Mina Therapeutics Ltd, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Naia Ltd, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by NeuroVive Pharmaceutical AB, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by NGM Biopharmaceuticals Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Nippon Chemiphar Co Ltd, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by NorthSea Therapeutics BV, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Novartis AG, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by NovaTarg Therapeutics Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Novo Nordisk AS, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Nuevolution AB, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by NuSirt Biopharma Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Oramed Pharmaceuticals Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Pfizer Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Pharmaxis Ltd, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Poxel SA, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Promethera Biosciences SA, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by ProMetic Life Sciences Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Protalix BioTherapeutics Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Redx Pharma Plc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Regulus Therapeutics Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by reMYND NV, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Ritter Pharmaceuticals Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Saje Pharma LLC, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Sancilio & Company Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Sanofi, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by ScandiCure AB, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Second Genome Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Seres Therapeutics Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Shire Plc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Sprint Bioscience AB, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Synlogic Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Terns Pharmaceuticals Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Tiziana Life Sciences Plc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by TRACON Pharmaceuticals Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Vascular Biogenics Ltd, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Verlyx Pharma Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Viking Therapeutics Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Visionary Pharmaceuticals Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by WAVE Life Sciences Ltd, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Zafgen Inc, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Pipeline by Zebra Discovery Ltd, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Dormant Projects, H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Dormant Projects, H2 2018 (Contd..1), H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Dormant Projects, H2 2018 (Contd..2), H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Dormant Projects, H2 2018 (Contd..3), H2 2018

Non-Alcoholic Steatohepatitis (NASH) – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports